Application US20220062238

INJECTABLE FORMULATIONS
[+] Show Details

US20220062238

1. A pharmaceutical formulation suitable for injection, comprising: (14) (4)

a salt of a dimethyltryptamine compound optionally substituted with deuterium and optionally substituted at position 4 or 5 with acetoxy or methoxy or position 4 with monohydrogen phosphate;

a buffer which is separate to the salt; and

water,

wherein the formulation has a pH of about 3.5 to about 6.5 and an osmolality of about 250 to about 350 mOsm/Kg.

2. The formulation of claim 1, wherein the pH is from about 3.75 to about 5.75. (0)

3. The formulation of claim 1, wherein the pH is from about 3.75 to about 4.25. (0)

4. The formulation of claim 1, wherein the formulation has an osmolality of about 275 to about 325 mOsm/Kg. (0)

5. The formulation of claim 1, wherein the salt of the dimethyltryptamine compound comprises a Brønsted acid having a pKa of from about 3 to about 5 and a compound of Formula I: (2) (4)

wherein:

R⁴and R⁵are both H and each ^xH and each ^YH is independently selected from H and D, or

one of R⁴and R⁵is H and the other is acetoxy or methoxy, each ^YH is H and each ^xH is independently selected from H and D, or

the salt comprises a compound of Formula I wherein R⁴is monohydrogen phosphate, R⁵is H and each ^YH and each ^xH is H.

6. The formulation of claim 5, wherein (0) (3)

20. A method of treating a psychiatric or neurological disorder comprising administering to a patient in need thereof a formulation as defined in claim 5. (0)

7. The formulation of claim 1, wherein the optionally substituted dimethyltryptamine compound is dimethyltryptamine. (0)

8. The formulation of claim 1, wherein the salt is of an optionally substituted dimethyltryptamine compound and an acid selected from the group consisting of fumaric acid, tartaric acid, citric acid, acetic acid, lactic acid and gluconic acid (0)

9. The formulation of claim 1, wherein the salt is of an optionally substituted dimethyltryptamine compound and wherein the acid is fumaric acid. (0)

10. The formulation of claim 1, wherein the salt of the dimethyltryptamine compound has a purity of greater than or equal to 99% when measured by HPLC. (0)

11. The formulation of claim 1, wherein the concentration of the optionally substituted dimethyltryptamine is about 2.5 mg/mL. (0)

12. The formulation of claim 1, wherein the buffer comprises sodium acetate and acetic acid, or potassium acetate and acetic acid. (0)

13. The formulation of claim 1, further comprising a tonicity agent. (1) (0)

15. The formulation of claim 1, wherein the formulation consists essentially of the salt, the buffer, water, and optionally a tonicity agent. (0)

16. The formulation of claim 1, wherein the formulation having an oxygen content of less than 2 ppm. (0)

17. A method of treating a psychiatric or neurological disorder comprising administering to a patient in need thereof a formulation as defined in claim 1. (1) (0)

View Abstract and Specification Size

PDF with Images and Document Face >

Full Text Publication >

Application US20220062238

INJECTABLE FORMULATIONS

Patent Matrix® Search